131 reports of this reaction
1.3% of all VONOPRAZAN FUMARATE reports
#19 most reported adverse reaction
HEPATIC FUNCTION ABNORMAL is the #19 most commonly reported adverse reaction for VONOPRAZAN FUMARATE. There are 131 FDA adverse event reports linking VONOPRAZAN FUMARATE to HEPATIC FUNCTION ABNORMAL. This represents approximately 1.3% of all 9,763 adverse event reports for this drug.
Patients taking VONOPRAZAN FUMARATE who experience hepatic function abnormal should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATIC FUNCTION ABNORMAL is a less commonly reported adverse event for VONOPRAZAN FUMARATE, but still significant enough to appear in the safety profile.
In addition to hepatic function abnormal, the following adverse reactions have been reported for VONOPRAZAN FUMARATE:
The following drugs have also been linked to hepatic function abnormal in FDA adverse event reports:
HEPATIC FUNCTION ABNORMAL has been reported as an adverse event in 131 FDA reports for VONOPRAZAN FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATIC FUNCTION ABNORMAL accounts for approximately 1.3% of all adverse event reports for VONOPRAZAN FUMARATE, making it a notable side effect.
If you experience hepatic function abnormal while taking VONOPRAZAN FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.